Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.
Kan S, Bai H, Liu H, Cui J, Ke X, Zhang H, Liu L, Yan D, Jiang Y, Zang A, Qi J, Wang L, Liu Z, Xu B, Zhang Y, Zhang Z, Zhao X, Hu C, Yang S, Zhou H, Shi J, Shao Z, Xiang Y, Lin N, Zhang M.
Kan S, et al. Among authors: zhang m.
Leuk Res. 2024 Nov 26;149:107633. doi: 10.1016/j.leukres.2024.107633. Online ahead of print.
Leuk Res. 2024.
PMID: 39799811